Auxiliary Blood Glucose-Lowering Function Testing for Health Supplements

Auxiliary blood glucose-lowering function testing provides scientific evidence that health supplements and functional foods can help maintain healthy blood sugar levels. Through standardized animal experiments and human feeding trials conducted in accredited third-party laboratories, manufacturers can substantiate functional claims, satisfy health food registration requirements, and demonstrate product safety and efficacy. This article explains the complete testing framework, sample requirements, evaluation items, methods, and regulatory applications.

Technical Overview

Auxiliary blood glucose-lowering function testing is a scientific evaluation designed to verify whether a health supplement can meaningfully assist in maintaining normal blood glucose levels without posing safety risks. In many jurisdictions, including China where this function claim is formally recognized, products bearing such a claim must complete a structured function evaluation program before market approval. The evaluation framework typically combines animal function experiments and human feeding trials, supported by comprehensive safety and hygiene assessments.

The testing regime is anchored in recognized national and international standards. In China, function evaluation follows the official technical specifications for health food inspection and evaluation, safety toxicology follows the GB 15193 series, and general hygiene requirements follow GB 16740 for health foods. Internationally, laboratory quality management is typically governed by ISO/IEC 17025 accreditation, while Good Laboratory Practice (GLP) principles govern toxicology studies. Together, these frameworks ensure that test results are reproducible, statistically valid, and acceptable to regulators.

The core scientific logic of the evaluation is twofold: first, the product must demonstrate a measurable glucose-lowering or glucose-regulating effect in validated hyperglycemia models or in human subjects with elevated blood glucose; second, the product must not induce excessive hypoglycemia in subjects with normal glucose levels, confirming a gentle, modulating action rather than a pharmacological drug-like effect.

Testing Samples

Common Dosage Forms

Function evaluation can be performed on virtually all mainstream health supplement dosage forms. Each form requires appropriate pre-treatment before administration to test animals or human subjects.

• Hard capsules and softgel capsules
• Tablets, chewable tablets, and effervescent tablets
• Oral liquids and liquid concentrates
• Granules, powders, and beverage premixes
• Functional teas and traditional herbal preparations
• Gummies and other novel delivery formats

Typical Functional Ingredients and Raw Materials

Products submitted for auxiliary blood glucose-lowering evaluation frequently contain botanical extracts, bioactive compounds, minerals, or dietary fibers with documented glucose-regulating potential.

• Botanical extracts: bitter melon, mulberry leaf, Gymnema sylvestre, fenugreek, cinnamon, American ginseng
• Bioactive compounds: berberine, chlorogenic acid, alpha-lipoic acid, soy isoflavones
• Minerals and trace elements: trivalent chromium (chromium picolinate), zinc, magnesium
• Dietary fibers and polysaccharides: konjac glucomannan, oat beta-glucan, pumpkin polysaccharides
• Probiotics and postbiotics targeting metabolic regulation

Sample Submission Requirements

To ensure representativeness, laboratories generally require samples from three consecutive production batches of the finished formulation intended for market. Sufficient quantity must be provided to cover animal dosing for the full study duration, human trial supply, physical-chemical analysis, microbiological testing, and retained backup samples. Samples should be within their intended shelf life, accompanied by the complete formula, ingredient specifications, recommended daily intake, production process description, and stability data where available.

Testing Items

The evaluation consists of three integrated modules: functional efficacy testing, safety toxicology, and hygiene quality control. The functional module is the decisive component for claim substantiation.

• Fasting blood glucose (FBG): the primary efficacy endpoint in both animal and human studies
• Oral glucose tolerance test (OGTT) with calculation of the area under the blood glucose-time curve (AUC)
• Glycated hemoglobin (HbA1c): reflecting long-term glycemic control over the preceding 8 to 12 weeks
• Serum insulin and C-peptide: assessing pancreatic beta-cell secretory function
• Insulin resistance indices such as HOMA-IR where applicable
• Liver glycogen content: evaluating glucose storage and metabolic regulation in animal models
• Body weight, food intake, and organ coefficients in animal studies
• Acute oral toxicity, genotoxicity battery, and 90-day subchronic toxicity per the GB 15193 series
• Microbiological limits and contaminant testing, including heavy metals, per GB 16740 and related national food safety standards

Testing Methods

Animal Function Experiments

Animal studies are conducted in rodents, typically mice or rats. Hyperglycemia models are established using chemically induced beta-cell damage, most commonly with streptozotocin (STZ) or alloxan administered after an overnight fast. Animals with confirmed sustained fasting hyperglycemia are randomized into a model control group, a positive control group, and three dose groups of the test sample, usually designed around the human recommended daily intake converted to animal-equivalent doses with appropriate safety factors. A parallel normal-animal group is included to verify that the product does not excessively reduce glucose in healthy subjects.

The test sample is administered daily by gavage for a standard period, generally 30 days. Fasting blood glucose is measured at baseline and at intervals during the study, and an OGTT is performed near the end of the dosing period. Blood glucose AUC, insulin levels, liver glycogen, body weight, and food consumption are recorded and analyzed statistically.

Human Feeding Trials

Human trials are randomized, double-blind, and placebo-controlled, conducted under medical supervision in qualified clinical settings. Eligible subjects are adults with impaired fasting glucose, impaired glucose tolerance, or mild type 2 diabetes with stable condition and stable medication where ethically permitted. Subjects with severe complications, pregnant or lactating women, and individuals taking medications that interfere with glucose metabolism are typically excluded.

After a run-in period, subjects are randomized to the test product or placebo and consume the product at the recommended daily dose for a trial period commonly lasting 30 to 60 days, with HbA1c evaluation requiring a longer observation window. Primary endpoints include fasting blood glucose and 2-hour postprandial glucose; secondary endpoints include HbA1c, insulin, and blood lipid parameters. Safety is monitored throughout via clinical examination, hematology, and clinical biochemistry.

Judgment Criteria

A positive functional result generally requires all of the following: fasting blood glucose in the test groups is significantly lower than the model control group or demonstrates a meaningful reduction from baseline; the OGTT area under the curve is reduced compared with the model control; and fasting glucose in normal animals is not significantly depressed, confirming the modulating rather than aggressive glucose-lowering character of the product. In human trials, significant improvement in fasting and postprandial glucose versus placebo, with no adverse safety signals, supports the functional claim.

Quality Assurance

All studies should be performed in accredited third-party laboratories operating under ISO/IEC 17025 quality management systems, with animal facilities holding appropriate laboratory animal use licenses and toxicology studies following GLP principles. Data are subjected to rigorous statistical analysis, and complete study reports include raw data, methodology, quality control records, and conclusions suitable for regulatory submission.

Applications

Auxiliary blood glucose-lowering function testing serves multiple business and regulatory purposes across the product lifecycle.

• Health food registration and certification: generating the function evaluation report required for product registration and the market approval mark in jurisdictions such as China
• Claim substantiation: providing scientific documentation supporting structure-function claims and marketing communications for domestic and export markets
• Formulation optimization: comparing candidate formulas, doses, and ingredient combinations during research and development
• International market access: satisfying evidence requirements for regulatory dossiers in markets that recognize scientifically substantiated health claims
• Risk management and consumer confidence: demonstrating that the product is both effective and safe, reducing regulatory and reputational risk
• Product re-registration and post-market surveillance support

FAQ

What sample quantity is required for a complete evaluation?

Typical requirements include several kilograms or liters of finished product per batch, drawn from three consecutive production batches, plus retained samples. Exact quantities depend on dosage form, recommended intake, and the scale of the human trial, and are confirmed in the test plan before commencement.

How long does the full evaluation take?

Animal experiments generally require approximately 6 to 10 weeks including model establishment and a 30-day dosing period. Human feeding trials require 2 to 4 months for recruitment, intervention, and follow-up, longer if HbA1c is a primary endpoint. Adding toxicology and hygiene testing, a complete registration-grade dossier typically takes 4 to 8 months.

Are both animal experiments and human trials mandatory?

For most registration pathways supporting an auxiliary blood glucose-lowering claim, both animal function experiments and human feeding trials are required, since the claim targets a metabolic function that must be validated in human subjects while animal data provide mechanistic and dose-response support. Specific requirements should be confirmed against the applicable regulatory framework for the target market.

What happens if the product lowers glucose too aggressively?

If the product significantly reduces blood glucose in normal, healthy animals or produces hypoglycemic episodes in human subjects, it fails the evaluation, because a health food is expected to modulate rather than forcibly lower glucose. Such results may also trigger additional safety review, and reformulation with dose adjustment is usually recommended.

Can testing support claims for diabetic patients?

Health supplements with auxiliary blood glucose-lowering claims are positioned for people with elevated blood glucose or impaired glucose regulation, not as replacements for diabetes medication. Human trial protocols carefully define inclusion criteria and prohibit modification of any prescribed therapy during the study, and product labeling must clearly state that the product is not a substitute for medical treatment.